当前位置: X-MOL 学术Curr. Opin. Pharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Microfluidics for personalized drug screening of cancer.
Current Opinion in Pharmacology ( IF 4 ) Pub Date : 2019-10-22 , DOI: 10.1016/j.coph.2019.09.008
Nishanth Venugopal Menon 1 , Su Bin Lim 2 , Chwee Teck Lim 3
Affiliation  

Resistance to targeted therapies is a major clinical challenge in cancer treatment. Despite technological advances, robust biomarkers or platforms predictive of treatment response are lacking owing to the inherent nature of complex genomic landscape of carcinoma. Nevertheless, recent efforts centred on performing direct drug screening on patient-derived cells through their ex vivo expansion and maintenance have enabled personalized stratification of treatment modalities. Microfluidics is one such technology that allows high-throughput drug screening through parallelization and automation using small-volume sample. In this review, we present recent microfluidic platforms that have been successfully applied for the maintenance and expansion of patient-derived tumor cells spanning diverse cancer types and sources (solid tumors or liquid biopsies (circulating tumor cells)) for personalized drug screening applications.

中文翻译:

微流控技术可用于癌症的个性化药物筛选。

对靶向疗法的抗性是癌症治疗中的主要临床挑战。尽管技术上有进步,但由于癌症复杂基因组格局的固有性质,仍缺乏可预测治疗反应的强大生物标志物或平台。然而,最近的努力集中在通过其体外扩增和维持对患者来源的细胞进行直接药物筛选上,从而实现了治疗方式的个性化分层。微流体技术就是这样一种技术,它允许使用少量样品通过并行化和自动化进行高通量药物筛选。在这篇评论中
更新日期:2019-10-18
down
wechat
bug